{
    "nctId": "NCT02393924",
    "briefTitle": "Human Epidermal Growth Factor Receptor 2 (HER2) Positive Unresectable Locally Advanced or Metastatic Breast Cancer Disease Registry Study",
    "officialTitle": "UK - A Disease Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 311,
    "primaryOutcomeMeasure": "Percentage of Participants Receiving Each Unique Treatment Regimen Overall",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Initially diagnosed with HER2-positive unresectable LABC or mBC no more than 6 months prior to enrollment, although they can have received anti-cancer treatment during that time\n* Able and willing to provide written informed consent and to comply with the study protocol\n\nExclusion Criteria:\n\n- There are no exclusion criteria for entry into this study",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}